Alnylam Pharmaceuticals Inc. has found a partner for its RNAi therapeutics program targeting PCSK9 for the treatment of high cholesterol in the hospital specialist The Medicines Co. The two companies announced a development and commercial alliance for Alnylam’s’ ALN-PCS program Feb. 4, marking TMC’s entrance into what has become one of the pharmaceutical industry’s most competitive fields of drug development.
The Medicines Co. Enters PCSK9 Race With Alnylam Deal
The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.